Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Trolle

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Elife|January 30, 2016
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding grooveCurtis McMurtrey, Thomas Trolle, Tiffany Sansom, et al.
FEMS Microbiology Reviews|July 16, 2015
Ebolavirus comparative genomicsSe-Ran Jun, Michael R Leuze, Intawat Nookaew, et al.
NPJ Vaccines|March 21, 2025
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesChristian Garde, Michail A Pavlidis, Pablo Garces, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Elife|January 30, 2016
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding grooveCurtis McMurtrey, Thomas Trolle, Tiffany Sansom, et al.
FEMS Microbiology Reviews|July 16, 2015
Ebolavirus comparative genomicsSe-Ran Jun, Michael R Leuze, Intawat Nookaew, et al.
NPJ Vaccines|March 21, 2025
Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccinesChristian Garde, Michail A Pavlidis, Pablo Garces, et al.
Oncoimmunology|January 17, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanomaSofie Kirial Mørk, Mohammad Kadivar, Kalijn Fredrike Bol, et al.
Pageof 2